UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 15, 2016
| AYTU BIOSCIENCE, INC. |
| (Exact Name of Registrant as Specified in Charter) |
| | | |
| Delaware | 000-53121 | 47-0883144 |
(State or Other Jurisdiction
of Incorporation) | (Commission
File Number) | (IRS Employer
Identification No.) |
| | | |
| 373 Inverness Parkway, Suite 206, Englewood, Colorado | 80112 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (720) 437-6580
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective May 15, 2016, we amended our employment agreement with Jonathan McGrael to change his title from Vice President of Sales to Vice President of Commercial Operations and increase his base salary from $175,000 to $190,000. All other terms remain the same. The original agreement was filed as Exhibit 10.17 to our Quarterly Report on Form 10-Q filed on November 6, 2015.
| Item 9.01. | Financial Statements and Exhibits. |
| 10.1 | First Amendment to Employment Agreement, dated as of May 15, 2016 and effective as of May 15, 2016, between Aytu BioScience, Inc. and Jonathan McGrael |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 16, 2016 | | AYTU BIOSCIENCE, INC. | |
| | | | | |
| | | | | |
| | | /s/ Gregory A. Gould | |
| | | Name: | Gregory A. Gould | |
| | | Title: | Chief Financial Officer | |
